Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives
Authors
Keywords
-
Journal
Lancet Gastroenterology & Hepatology
Volume 7, Issue 2, Pages 171-185
Publisher
Elsevier BV
Online
2022-01-11
DOI
10.1016/s2468-1253(21)00223-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?
- (2021) Tasnim Abdalla et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease
- (2021) Kaija-Leena Kolho Frontiers in Pediatrics
- Advances in the optimization of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-α antagonists
- (2021) Kata Judit Szántó et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease
- (2021) Neasa Mc Gettigan et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases
- (2021) Silje Watterdal Syversen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms
- (2021) Bella Ungar et al. Journal of Crohns & Colitis
- A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease
- (2021) Adam S. Cheifetz et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A 3‐year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease
- (2020) José Germán Sánchez‐Hernández et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission
- (2020) Jurij Hanžel et al. Clinical Gastroenterology and Hepatology
- Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients
- (2020) Xiaoliang Ding et al. CTS-Clinical and Translational Science
- Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial
- (2020) Xavier Roblin et al. GUT
- The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis
- (2020) Martin Perry et al. Therapeutic Advances in Musculoskeletal Disease
- Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD
- (2020) Evy Ulijn et al. ANNALS OF THE RHEUMATIC DISEASES
- Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors
- (2020) Caterina Bodio et al. AUTOIMMUNITY REVIEWS
- Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients with Crohn's Disease
- (2020) Erwin Dreesen et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases
- (2020) Konstantinos Papamichail et al. Clinical Gastroenterology and Hepatology
- Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease
- (2020) Peter Bossuyt et al. Clinical Gastroenterology and Hepatology
- Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With infliximab
- (2020) Niels Vande Casteele et al. Clinical Gastroenterology and Hepatology
- Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlate With Rate of Infection
- (2020) Amandine Landemaine et al. Clinical Gastroenterology and Hepatology
- Baseline Clearance of Infliximab is Associated with Requirement for Colectomy in Patients with Acute Severe Ulcerative Colitis
- (2020) Robert Battat et al. Clinical Gastroenterology and Hepatology
- Innovation in IBD Care During the COVID-19 Pandemic: Results of a Global Telemedicine Survey by the International Organization for the Study of Inflammatory Bowel Disease
- (2020) Charlie W. Lees et al. GASTROENTEROLOGY
- Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease
- (2020) John L Lyles et al. INFLAMMATORY BOWEL DISEASES
- Serum Adalimumab Concentration after Surgery is Correlated with Postoperative Endoscopic Recurrence in Crohn’s Disease Patients: One Step before Proactive Therapeutic Drug Monitoring
- (2020) Lucile Boivineau et al. Journal of Crohns & Colitis
- Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study
- (2020) Mark A. Samaan et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Pharmacogenetics of trough serum anti‐TNF levels in paediatric inflammatory bowel disease
- (2020) Sara Salvador‐Martín et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology
- (2020) Konstantinos Papamichael et al. CURRENT OPINION IN RHEUMATOLOGY
- Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease
- (2020) Sine Buhl et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach—an Indian experience
- (2020) Mihika B. Dave et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label
- (2020) Sebastian Stefanovic et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Association of Early Postinduction Adalimumab Exposure With Subsequent Clinical and Biomarker Remission in Children with Crohn’s Disease
- (2020) Firas Rinawi et al. INFLAMMATORY BOWEL DISEASES
- Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn’s Disease
- (2020) Ruben J Colman et al. INFLAMMATORY BOWEL DISEASES
- Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey
- (2020) Lisa Schots et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease
- (2020) Konstantinos Papamichael et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Real‐World Infliximab Pharmacokinetic Study Informs an Electronic Health Record‐Embedded Dashboard to Guide Precision Dosing in Children with Crohn’s Disease
- (2020) Ye Xiong et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issues
- (2020) Zhigang Wang et al. CURRENT OPINION IN PHARMACOLOGY
- Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease
- (2020) Richard P McNeill et al. CURRENT OPINION IN PHARMACOLOGY
- Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations
- (2020) Nathalie Van den Berghe et al. Journal of Crohns & Colitis
- Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial
- (2020) Anne S. Strik et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation
- (2019) Mark T. Osterman et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
- (2019) Jurij Hanžel et al. United European Gastroenterology Journal
- Comparison of immunoassays for measuring serum levels of golimumab and antibodies against golimumab in ulcerative colitis
- (2019) Anne-Emmanuelle Berger et al. THERAPEUTIC DRUG MONITORING
- Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis
- (2019) José Miguel Senabre Gallego et al. RHEUMATOLOGY INTERNATIONAL
- Development of Infliximab Target Concentrations during Induction in Pediatric Crohnʼs Disease Patients
- (2019) Kathryn Clarkston et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn’s Disease: A Prospective Multicentre Study
- (2019) Niels Vande Casteele et al. Journal of Crohns & Colitis
- Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease
- (2019) Konstantinos Papamichael et al. Journal of Crohns & Colitis
- Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates
- (2019) Bram Verstockt et al. Journal of Crohns & Colitis
- Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases
- (2019) Andres J. Yarur et al. DIGESTIVE DISEASES AND SCIENCES
- Pharmacokinetic parameters of infliximab influence the rate of relapse after de-escalation in adults with inflammatory bowel diseases
- (2019) Antoine Petitcollin et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn’s Disease
- (2019) Ninon Soufflet et al. Clinical Gastroenterology and Hepatology
- Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease
- (2019) David Drobne et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation
- (2019) Sophie E. Berends et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical response correlates with 4‐week post injection ustekinumab concentrations in moderate‐to‐severe psoriasis patients
- (2019) N. Van den Berghe et al. BRITISH JOURNAL OF DERMATOLOGY
- Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease
- (2019) Erwin Dreesen et al. Clinical Gastroenterology and Hepatology
- Defining a minimal effective serum trough concentration of secukinumab in psoriasis: a step towards personalized therapy
- (2019) Rani Soenen et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine
- (2019) Pavine L. C. Lefevre et al. BIODRUGS
- Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases
- (2019) Konstantinos Papamichael et al. Expert Review of Clinical Immunology
- Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease
- (2019) Mark Löwenberg et al. GASTROENTEROLOGY
- Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn’s Disease Compared with Reactive Monitoring
- (2019) Amit Assa et al. GASTROENTEROLOGY
- Anti-drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as-needed infliximab treatment
- (2019) Abhishek Patil et al. International Journal of Rheumatic Diseases
- Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
- (2019) Nicholas A Kennedy et al. Lancet Gastroenterology & Hepatology
- Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response
- (2019) Miles P Sparrow et al. Journal of Crohns & Colitis
- Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
- (2019) Teresa Tsakok et al. JAMA Dermatology
- Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
- (2019) Luisa Guidi et al. United European Gastroenterology Journal
- HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease
- (2019) Aze Wilson et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- How, When, and For Whom Should We Perform Therapeutic Drug Monitoring?
- (2019) Severine Vermeire et al. Clinical Gastroenterology and Hepatology
- Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn’s Disease
- (2019) Claire Painchart et al. DIGESTIVE DISEASES AND SCIENCES
- Association between infliximab concentrations and clinical response in psoriasis: a prospective cohort study
- (2019) M. Colls-Gonzalez et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis
- (2019) Omoniyi J. Adedokun et al. Clinical Gastroenterology and Hepatology
- HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
- (2019) Aleksejs Sazonovs et al. GASTROENTEROLOGY
- Anti-infliximab antibodies: How to compare old and new data?
- (2019) Maya Imbrechts et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients
- (2018) D. Dutzer et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study
- (2018) W. Yacoub et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Letter: infliximab concentrations during induction therapy-one size does not fit all
- (2018) K. Papamichael et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study
- (2018) Bella Ungar et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD
- (2018) Yara Nasser et al. DIGESTIVE DISEASES AND SCIENCES
- Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
- (2018) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease
- (2018) Geert D’Haens et al. GASTROENTEROLOGY
- Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn’s Disease in Children
- (2018) Wael El-Matary et al. INFLAMMATORY BOWEL DISEASES
- Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD
- (2018) Sara Lega et al. INFLAMMATORY BOWEL DISEASES
- A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease
- (2018) Travis Piester et al. INFLAMMATORY BOWEL DISEASES
- A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF
- (2018) Patricia Romero-Cara et al. International Journal of Medical Sciences
- Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis
- (2018) Emmanuel Chigutsa et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System
- (2018) Alexander Eser et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn’s Disease
- (2018) Emily K Wright et al. Journal of Crohns & Colitis
- Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis
- (2018) David Kevans et al. Journal of Crohns & Colitis
- Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease
- (2018) Konstantinos Papamichael et al. Journal of Crohns & Colitis
- Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks
- (2018) M. Toro-Montecinos et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis
- (2018) Kristian Reich et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study
- (2018) Alejandro Balsa et al. RHEUMATOLOGY
- Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing
- (2018) Bram Verstockt et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study
- (2018) Nina Wilkinson et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up
- (2018) E. H. Vogelzang et al. PLoS One
- Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information
- (2018) Iris Detrez et al. AAPS Journal
- Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring
- (2018) Camille Lucidarme et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Infliximab Exposure-Response Relationship and Thresholds Associated with Endoscopic Healing in Patients With Ulcerative Colitis
- (2018) Niels Vande Casteele et al. Clinical Gastroenterology and Hepatology
- Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement
- (2017) CAM Bouman et al. Expert Opinion on Drug Metabolism & Toxicology
- Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort
- (2017) Lorant Gonczi et al. INFLAMMATORY BOWEL DISEASES
- Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice
- (2017) Mariam Aguas Peris et al. INFLAMMATORY BOWEL DISEASES
- Efficacy of Home Telemonitoring versus Conventional Follow-up: A Randomized Controlled Trial among Teenagers with Inflammatory Bowel Disease
- (2017) Anke Heida et al. Journal of Crohns & Colitis
- Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis
- (2017) J. M. Carrascosa et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial
- (2017) Marin J de Jong et al. LANCET
- Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients
- (2016) Marla C. Dubinsky et al. AAPS Journal
- Postoperative Complications after Ileocecal Resection in Crohn’s Disease: A Prospective Study From the REMIND Group
- (2016) Mathurin Fumery et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease
- (2016) Thomas Billiet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort
- (2016) Meghna Jani et al. ANNALS OF THE RHEUMATIC DISEASES
- Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis
- (2016) Johannan F. Brandse et al. Clinical Gastroenterology and Hepatology
- Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection
- (2016) Miguel Regueiro et al. GASTROENTEROLOGY
- Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples
- (2016) Ann Gils et al. INFLAMMATORY BOWEL DISEASES
- Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohnʼs Disease
- (2016) Ronen Stein et al. INFLAMMATORY BOWEL DISEASES
- Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
- (2016) Omoniyi J. Adedokun et al. Journal of Crohns & Colitis
- Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis
- (2016) Klaudia Farkas et al. Journal of Crohns & Colitis
- Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study
- (2016) EL Kneepkens et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value
- (2016) Laida Elberdín et al. International Journal of Clinical Pharmacy
- Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis
- (2016) Désirée van der Heijde et al. Arthritis & Rheumatology
- Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation
- (2016) Thomas Van Stappen et al. Clinical and Translational Gastroenterology
- Factors Associated With Short- and Long-Term Outcomes of Therapy for Crohn’s Disease
- (2015) Walter Reinisch et al. Clinical Gastroenterology and Hepatology
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Immunogenicity to infliximab is associated with HLA-DRB1
- (2015) Thomas Billiet et al. GUT
- The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
- (2015) Andres J Yarur et al. GUT
- An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases
- (2015) Thomas Van Stappen et al. INFLAMMATORY BOWEL DISEASES
- Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases?
- (2015) Jo Lambert et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
- (2015) Taku Kobayashi et al. JOURNAL OF GASTROENTEROLOGY
- Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up
- (2015) Der-Yuan Chen et al. RHEUMATOLOGY
- Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis
- (2015) Stef P. Menting et al. JAMA Dermatology
- Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis
- (2015) Meghna Jani et al. Arthritis & Rheumatology
- Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis
- (2014) Der-Yuan Chen et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up
- (2014) Erik H Vogelzang et al. ANNALS OF THE RHEUMATIC DISEASES
- Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice
- (2014) Eva L Kneepkens et al. ANNALS OF THE RHEUMATIC DISEASES
- Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up
- (2014) E L Kneepkens et al. ANNALS OF THE RHEUMATIC DISEASES
- Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab
- (2014) Giorgia Bodini et al. DIGESTIVE AND LIVER DISEASE
- Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
- (2014) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease
- (2014) Byron P. Vaughn et al. INFLAMMATORY BOWEL DISEASES
- Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation
- (2014) Jacqueline E Paramarta et al. ARTHRITIS RESEARCH & THERAPY
- Monitoring Drug and Antidrug Levels: A Rational Approach in Rheumatoid Arthritis Patients Treated with Biologic Agents Who Experience Inadequate Response While Being on a Stable Biologic Treatment
- (2014) Diana Mazilu et al. Biomed Research International
- Key findings towards optimising adalimumab treatment: the concentration–effect curve
- (2013) Mieke F Pouw et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up
- (2013) Eva L Kneepkens et al. ANNALS OF THE RHEUMATIC DISEASES
- The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis
- (2013) Bart J. F. van den Bemt et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study
- (2013) S.K. Mahil et al. BRITISH JOURNAL OF DERMATOLOGY
- Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
- (2013) Jean–Frédéric Colombel et al. Clinical Gastroenterology and Hepatology
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
- (2013) Chamaida Plasencia et al. ARTHRITIS RESEARCH & THERAPY
- Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab
- (2012) Chamaida Plasencia et al. ANNALS OF THE RHEUMATIC DISEASES
- Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis
- (2012) Hidetoshi Takahashi et al. JOURNAL OF DERMATOLOGY
- Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients
- (2011) A Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
- (2011) Emilie Ducourau et al. ARTHRITIS RESEARCH & THERAPY
- Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis
- (2010) A. W. R. van Kuijk et al. ANNALS OF THE RHEUMATIC DISEASES
- Trough Infliximab Concentrations Predict Efficacy and Sustained Control of Disease Activity in Rheumatoid Arthritis
- (2010) Denis Mulleman et al. THERAPEUTIC DRUG MONITORING
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
- (2009) G. M. Bartelds et al. ANNALS OF THE RHEUMATIC DISEASES
- Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control study
- (2009) Roman Krzysiek et al. ARTHRITIS AND RHEUMATISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More